{"id":"diphenhydramine-5","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Drowsiness/sedation"},{"rate":"5-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Anticholinergic effects (urinary retention, constipation)"}]},"_chembl":null,"_dailymed":{"setId":"57a751e9-d8b6-4527-8537-bc4be718f5ec","title":"NIGHTTIME SLEEP AID (DIPHENHYDRAMINE HCL 50MG) CAPSULE, LIQUID FILLED [GROCERY OUTLET]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diphenhydramine competitively antagonizes H1 histamine receptors on various tissues, preventing histamine-mediated effects such as itching, urticaria, and allergic reactions. As a first-generation antihistamine, it crosses the blood-brain barrier and also possesses anticholinergic and sedating properties due to central nervous system penetration.","oneSentence":"Diphenhydramine is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:02:25.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic reactions and urticaria"},{"name":"Pruritus (itching)"},{"name":"Allergic rhinitis"},{"name":"Motion sickness and nausea"}]},"trialDetails":[{"nctId":"NCT05540574","phase":"PHASE2","title":"Trial of Zolpidem for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT07136415","phase":"PHASE4","title":"Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-13","conditions":"Menopausal Women, Insomnia","enrollment":1000},{"nctId":"NCT07472270","phase":"PHASE1","title":"Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2026-03-15","conditions":"Liver Cirrhosis","enrollment":12},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT05896228","phase":"PHASE2","title":"Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Benjamin T Diamond, MD","startDate":"2024-02-20","conditions":"Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":30},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT05662228","phase":"PHASE2","title":"Therapies for Down Syndrome Regression Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-29","conditions":"Down Syndrome, Regression","enrollment":66},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07235748","phase":"PHASE1","title":"Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-10-07","conditions":"Healthy Adult Participants","enrollment":28},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":"Multiple Sclerosis","enrollment":864},{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Lupus Nephritis","enrollment":271},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT06962631","phase":"PHASE3","title":"V-IMMUNE® for Immune Thrombocytopenia","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-07-18","conditions":"Immune Thrombocytopenia (ITP)","enrollment":31},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT06083571","phase":"PHASE2","title":"Intranasal Ketorolac Trial","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2024-01-01","conditions":"Headache, Migraine","enrollment":41},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02535416","phase":"PHASE1","title":"A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":"Renal Insufficiency, Chronic, Hyperkalemia","enrollment":1112},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07324889","phase":"PHASE1, PHASE2","title":"An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yihao Wang","startDate":"2026-01-31","conditions":"Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","enrollment":24},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":118},{"nctId":"NCT07285031","phase":"NA","title":"Histamines and Central Hemodynamics","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12","conditions":"Histamine, Exercise","enrollment":20},{"nctId":"NCT06070649","phase":"PHASE1","title":"The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-08-04","conditions":"Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use","enrollment":63},{"nctId":"NCT04548999","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":769},{"nctId":"NCT03997851","phase":"PHASE1, PHASE2","title":"Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects","status":"COMPLETED","sponsor":"University of Miami","startDate":"2019-07-22","conditions":"Pruritus","enrollment":17},{"nctId":"NCT07259070","phase":"PHASE1, PHASE2","title":"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-11-29","conditions":"DLBCL, CLL, FL","enrollment":20},{"nctId":"NCT06120673","phase":"PHASE3","title":"REmission in Membranous Nephropathy International Trial (REMIT)","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2025-10-31","conditions":"Primary Membranous Nephropathy","enrollment":""},{"nctId":"NCT05077800","phase":"PHASE2","title":"FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-03-21","conditions":"Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic","enrollment":70},{"nctId":"NCT04456439","phase":"","title":"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast International Sàrl","startDate":"","conditions":"Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","enrollment":""},{"nctId":"NCT05285813","phase":"PHASE2","title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-05-06","conditions":"AML, MDS","enrollment":42},{"nctId":"NCT04606264","phase":"PHASE3","title":"Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data","status":"COMPLETED","sponsor":"Jennifer Holder-Murray","startDate":"2023-05-15","conditions":"Perioperative Optimization","enrollment":2977},{"nctId":"NCT05215236","phase":"NA","title":"Opiate Sparing Protocol Randomized Controlled Trial in Open Distal Radius Fracture Repair","status":"COMPLETED","sponsor":"Campbell Clinic","startDate":"2022-03-01","conditions":"Distal Radius Fracture","enrollment":72},{"nctId":"NCT07207057","phase":"PHASE3","title":"Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial","status":"RECRUITING","sponsor":"University College, London","startDate":"2025-09-12","conditions":"Parkinsons Disease (PD)","enrollment":1200},{"nctId":"NCT03563248","phase":"PHASE2","title":"Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-08-10","conditions":"Pancreatic Cancer","enrollment":168},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT05402397","phase":"PHASE4","title":"Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies","status":"COMPLETED","sponsor":"Hospital General de Niños Pedro de Elizalde","startDate":"2022-07-01","conditions":"Uric Acid Nephropathy","enrollment":40},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT07095049","phase":"PHASE1","title":"Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Interna Therapeutics Ltd.","startDate":"2024-09-04","conditions":"SARS-CoV-2 (COVID-19) Infection","enrollment":56},{"nctId":"NCT03805932","phase":"PHASE1","title":"Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-03","conditions":"Hairy Cell Leukemia","enrollment":18},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT06980454","phase":"PHASE1","title":"Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-06-04","conditions":"Cancer, mCRC","enrollment":322},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT03762850","phase":"PHASE3","title":"A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Travere Therapeutics, Inc.","startDate":"2018-12-11","conditions":"Immunoglobulin A Nephropathy","enrollment":406},{"nctId":"NCT03448393","phase":"PHASE1","title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-26","conditions":"Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma","enrollment":54},{"nctId":"NCT04518293","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-07-09","conditions":"Hypertension","enrollment":1385},{"nctId":"NCT03554473","phase":"PHASE1, PHASE2","title":"M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-11","conditions":"Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT06648681","phase":"PHASE2","title":"Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-05-01","conditions":"Delirium - Postoperative, Cardiac Surgery, Cardiac Surgery Subjects","enrollment":60},{"nctId":"NCT04106856","phase":"PHASE1","title":"Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2019-08-08","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma","enrollment":22},{"nctId":"NCT06823284","phase":"PHASE1","title":"To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects","status":"COMPLETED","sponsor":"Teikoku Seiyaku Co., Ltd.","startDate":"2025-01-21","conditions":"Healthy","enrollment":26},{"nctId":"NCT00429364","phase":"PHASE3","title":"Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2007-01","conditions":"Marfan Syndrome","enrollment":608},{"nctId":"NCT04599634","phase":"PHASE1","title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-16","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma","enrollment":11},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT06557330","phase":"PHASE2","title":"MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2025-06","conditions":"Lymphoma, Indolent Non-hodgkin Lymphoma","enrollment":24},{"nctId":"NCT03030417","phase":"PHASE1","title":"Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-27","conditions":"Solid Tumors, Lymphoma","enrollment":36},{"nctId":"NCT06282549","phase":"","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2022-06-08","conditions":"Essential Hypertension","enrollment":1219},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":"Hypertension","enrollment":381},{"nctId":"NCT03688464","phase":"EARLY_PHASE1","title":"Treatment of Nighttime Pruritus in Atopic Dermatitis","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2019-02-02","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT06561035","phase":"PHASE3","title":"ACL-R Opioid Sparing Study","status":"ENROLLING_BY_INVITATION","sponsor":"Campbell Clinic","startDate":"2024-09-01","conditions":"Anterior Cruciate Ligament Injuries","enrollment":56},{"nctId":"NCT06531837","phase":"NA","title":"Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-08-25","conditions":"Chronic Pain","enrollment":60},{"nctId":"NCT06519344","phase":"EARLY_PHASE1","title":"An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Tongji Hospital, Tongji University School of Medicine","startDate":"2024-07-31","conditions":"B Cell Malignancies","enrollment":12},{"nctId":"NCT06084845","phase":"PHASE2","title":"Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer","status":"WITHDRAWN","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2024-04-12","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT01244815","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-16","conditions":"Bipolar Disorder, Pediatric","enrollment":404},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03185130","phase":"PHASE4","title":"Intravenous Fluids in Benign Headaches Trial","status":"COMPLETED","sponsor":"University Medical Center of Southern Nevada","startDate":"2017-05-16","conditions":"Headache","enrollment":58},{"nctId":"NCT00568178","phase":"PHASE3","title":"An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06-01","conditions":"Proteinuria","enrollment":306},{"nctId":"NCT01349907","phase":"PHASE3","title":"Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-16","conditions":"Bipolar Disorder","enrollment":322},{"nctId":"NCT04846348","phase":"PHASE2","title":"Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis","status":"TERMINATED","sponsor":"Joseph Butterfield","startDate":"2021-07-26","conditions":"Cutaneous Mastocytoses","enrollment":1},{"nctId":"NCT06375161","phase":"EARLY_PHASE1","title":"Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.","status":"RECRUITING","sponsor":"Shanghai Tongji Hospital, Tongji University School of Medicine","startDate":"2023-12-11","conditions":"B Cell Malignancies","enrollment":12},{"nctId":"NCT03338764","phase":"PHASE3","title":"An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia","status":"WITHDRAWN","sponsor":"Sequential Medicine Ltd","startDate":"2023-05","conditions":"Transient Insomnia","enrollment":""},{"nctId":"NCT04633967","phase":"","title":"Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.","status":"COMPLETED","sponsor":"Maritime Neurology","startDate":"2016-05-15","conditions":"Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis","enrollment":30},{"nctId":"NCT06299488","phase":"NA","title":"Combined Effects of Prunus Cerasus and Apocynum Venetum On Sleep and Anxiety in Adults With Insomnia","status":"COMPLETED","sponsor":"Lakshmi Nutraceuticals LLC","startDate":"2023-04-05","conditions":"Insomnia","enrollment":77},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT00456963","phase":"PHASE4","title":"Prevention of Diabetes and Hypertension","status":"TERMINATED","sponsor":"Istituto Auxologico Italiano","startDate":"2007-09","conditions":"Diabetes Mellitus, Hypertension","enrollment":3000},{"nctId":"NCT04840615","phase":"PHASE1","title":"Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-11","conditions":"Mesothelioma","enrollment":2},{"nctId":"NCT06217367","phase":"PHASE4","title":"Over-the-Counter Antihistamines & Heat Stress","status":"UNKNOWN","sponsor":"Lakehead University","startDate":"2023-12-05","conditions":"Heat Illness, Allergic Rhinitis, Heat Injury","enrollment":16},{"nctId":"NCT04425902","phase":"PHASE1","title":"Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-12-16","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT05302388","phase":"PHASE1","title":"A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-04-11","conditions":"Asymptomatic Hyperuricemia","enrollment":45},{"nctId":"NCT00274599","phase":"PHASE4","title":"PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-10-09","conditions":"Hypertension","enrollment":812},{"nctId":"NCT05126849","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-01-06","conditions":"Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":31},{"nctId":"NCT06063109","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.","status":"COMPLETED","sponsor":"THPharm Corp.","startDate":"2023-10-09","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":51},{"nctId":"NCT04308837","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation","status":"UNKNOWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-12-03","conditions":"Gastric Cancer, Stomach Cancer","enrollment":29},{"nctId":"NCT05673590","phase":"PHASE3","title":"Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2023-05-12","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":612},{"nctId":"NCT02272790","phase":"PHASE2","title":"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-30","conditions":"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation","enrollment":95},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1734,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Diphenhydramine 5%","genericName":"Diphenhydramine 5%","companyName":"Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology","companyId":"federal-state-budgetary-scientific-institution-research-institute-of-fundamental","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diphenhydramine is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses. Used for Allergic reactions and urticaria, Pruritus (itching), Allergic rhinitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}